title: A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk.
abstract: Stress increases drug craving and relapse risk. The kappa opioid receptor gene (OPRK1) mediates stress responses. Here, we examined whether the OPRK1 rs6989250 C>G affects stress-induced cocaine craving and cortisol responses, subsequent cocaine relapse risk and the neural response to stress using functional magnetic resonance imaging (fMRI) in cocaine dependence. Sixty-seven treatment-engaged, abstinent cocaine-dependent African-Americans were genotyped (CG: N=10; CC: N=57) and participated in a 3-day experiment in which they were exposed to personalized script-driven imagery of stress, drug cues and neutral scenarios, one condition per day, randomly assigned and counterbalanced across subjects. Repeated measures of craving and cortisol were obtained. The subjects were followed prospectively for 90 days to assess relapse risk. A follow-up preliminary fMRI experiment assessed neural responses to stress, drug cue and neutral conditions in matched CG (N=5) and CC (N=8) subgroups. We found greater stress-induced craving (P=0.019), higher cortisol during stress and cue relative to the neutral condition (P's<0.003), and increased cocaine relapse risk (P=0.0075) in the CG compared with the CC group. The CG relative to the CC group also showed greater activation of limbic and midbrain regions during stress and cues relative to the neutral condition with additional stress-induced activation in the right amygdala/hippocampus (P<0.05, whole-brain corrected). These results suggest that OPRK1 is associated with stress-induced craving and cortisol, hyperactive hypothalamus/thalamus-midbrain-cerebellum responses, and also associated with greater subsequent cocaine relapse risk. Future studies to replicate these findings in a larger sample size are warranted.
authors: Department of Psychiatry, Yale School of Medicine, New Haven, CT 06519, USA.
authors: K
authors: K
authors: Xu
authors: D
authors: D
authors: Seo
authors: C
authors: C
authors: Hodgkinson
authors: Y
authors: Y
authors: Hu
authors: D
authors: D
authors: Goldman
authors: R
authors: R
authors: Sinha
mesh_terms: D000328:Adult; D001741:Black or African American / Q000235:genetics / Q000523:psychology; D000679:Amygdala / Q000503:physiopathology; D001921:Brain / Q000503:physiopathology*; D002531:Cerebellum / Q000503:physiopathology; D003042:Cocaine / Q000009:adverse effects*; D019970:Cocaine-Related Disorders / Q000235:genetics* / Q000503:physiopathology; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects*; D005260:Female; D059907:Functional Neuroimaging; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism / Q000503:physiopathology; D007031:Hypothalamus / Q000503:physiopathology; D008032:Limbic System / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008636:Mesencephalon / Q000503:physiopathology; D008875:Middle Aged; D010913:Pituitary-Adrenal System / Q000378:metabolism / Q000503:physiopathology; D017473:Receptors, Opioid, kappa / Q000235:genetics*; D012008:Recurrence; D013315:Stress, Psychological / Q000235:genetics* / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000235:genetics* / Q000503:physiopathology; D013788:Thalamus / Q000503:physiopathology
chemical_list: D018765:Dopamine Uptake Inhibitors; C515653:OPRK1 protein, human; D017473:Receptors, Opioid, kappa; D003042:Cocaine; D006854:Hydrocortisone
references: Life Sci. 2000 Jan 21;66(9):803-15
references: 10698355
references: Neuropsychopharmacology. 2009 Apr;34(5):1198-208
references: 18563062
references: Alcohol Alcohol. 2008 Sep-Oct;43(5):505-15
references: 18477577
references: J Pharmacol Exp Ther. 2006 Jan;316(1):440-7
references: 16223871
references: Alcohol. 2003 Jan;29(1):39-49
references: 12657375
references: Psychopharmacology (Berl). 2001 Dec;158(4):343-59
references: 11797055
references: Life Sci. 2003 Jun 27;73(6):749-58
references: 12801596
references: Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):771-5
references: 17373729
references: Neuropsychopharmacology. 2006 Apr;31(4):787-94
references: 16123754
references: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2938-42
references: 16477003
references: Psychopharmacology (Berl). 2005 Dec;183(2):171-80
references: 16163517
references: Mol Psychiatry. 2008 May;13(5):531-43
references: 17622222
references: Hum Brain Mapp. 2013 Oct;34(10):2561-73
references: 22504779
references: Addict Biol. 2009 Jan;14(1):84-98
references: 18945295
references: Brain Res. 2010 Feb 16;1314:44-55
references: 19716811
references: Ann N Y Acad Sci. 2008 Oct;1141:105-30
references: 18991954
references: Brain Res. 1987 Sep 22;421(1-2):373-6
references: 2825911
references: Cereb Cortex. 2007 Jun;17(6):1307-13
references: 16880223
references: Trends Neurosci. 2012 Oct;35(10):587-96
references: 22709632
references: CNS Drug Rev. 2003 Summer;9(2):187-98
references: 12847558
references: J Neurosci. 2004 Aug 4;24(31):6912-9
references: 15295026
references: Arch Gen Psychiatry. 2011 Sep;68(9):942-52
references: 21536969
references: Alcohol Clin Exp Res. 2005 Feb;29(2):185-95
references: 15714042
references: Br J Pharmacol. 1997 Mar;120(5):781-4
references: 9138682
references: Prog Neurobiol. 1995 Aug;46(6):575-605
references: 8545545
references: Exp Clin Psychopharmacol. 2007 Apr;15(2):134-43
references: 17469937
references: Neuron. 2008 Jul 10;59(1):11-34
references: 18614026
references: Emotion. 2007 May;7(2):227-38
references: 17516802
references: J Neurosci. 2008 Jan 9;28(2):407-14
references: 18184783
references: Neuropsychopharmacology. 2006 Jun;31(6):1241-8
references: 16123746
references: Pharmacol Biochem Behav. 2012 Dec;103(2):253-9
references: 22954510
references: Hum Mol Genet. 2008 Jun 15;17(12):1783-9
references: 18319328
references: Neuroimage. 1996 Dec;4(3 Pt 1):223-35
references: 9345513
references: Neurosci Biobehav Rev. 2010 Nov;35(2):151-6
references: 20438754
references: Comput Biomed Res. 1996 Jun;29(3):162-73
references: 8812068
references: Alcohol Clin Exp Res. 2007 Apr;31(4):555-63
references: 17374034
references: Neuroendocrinology. 1986;44(1):36-40
references: 3024056
references: J Comput Assist Tomogr. 1998 Mar-Apr;22(2):324-33
references: 9530404
references: Curr Top Behav Neurosci. 2013;13:379-402
references: 21769721
references: Alcohol Clin Exp Res. 2004 Jan;28(1):15-9
references: 14745298
references: Neuroimage. 2004;23 Suppl 1:S34-45
references: 15501099
references: Int J Neuropsychopharmacol. 2013 Jun;16(5):975-85
references: 23101464
references: Psychopharmacology (Berl). 2000 Oct;152(2):140-8
references: 11057517
references: Trends Neurosci. 1995 Jan;18(1):22-9
references: 7535487
references: Psychoneuroendocrinology. 2005 Oct;30(9):880-91
references: 15975729
references: Psychopharmacology (Berl). 2003 Oct;170(1):62-72
references: 12845411
references: Psychopharmacology (Berl). 2010 Jun;210(2):121-35
references: 20352414
references: Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1680-5
references: 9990084
references: Genetics. 2000 Jun;155(2):945-59
references: 10835412
references: Mol Psychiatry. 2006 Nov;11(11):1016-24
references: 16924269
references: Brain Res. 1987 Jun 16;413(2):213-9
references: 2886190
references: Psychoneuroendocrinology. 2008 May;33(4):478-86
references: 18325678
references: Arch Gen Psychiatry. 2006 Mar;63(3):324-31
references: 16520439
references: J Pharmacol Exp Ther. 2003 Apr;305(1):323-30
references: 12649385
references: Hum Brain Mapp. 2011 Nov;32(11):1998-2013
references: 21162046
references: Curr Psychiatry Rep. 2011 Oct;13(5):398-405
references: 21792580
references: Synapse. 1993 Apr;13(4):357-69
references: 7683144
references: J Pharmacol Exp Ther. 1993 Jan;264(1):489-95
references: 8093731
references: Psychoneuroendocrinology. 2008 May;33(4):425-36
references: 18280051
references: Science. 1986 Aug 15;233(4765):774-6
references: 3016896